Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial by unknown
RESEARCH ARTICLE Open Access
Effects of intravenous iron on fibroblast
growth factor 23 (FGF23) in haemodialysis
patients: a randomized controlled trial
Matthew A. Roberts1,2, Louis Huang1,2, Darren Lee1,2, Robert MacGinley1,2, Stefanie M. A. Troster2,
Annette B. Kent1,2, Sukhvinder S. Bansal3, Iain C. Macdougall4 and Lawrence P. McMahon1,2*
Abstract
Background: Intravenous iron affects serum levels of intact fibroblast growth factor-23 (iFGF23) and its cleavage
product c-terminal FGF23 (cFGF23) in iron-deficient people with normal renal function. We hypothesized that
intravenous iron modulates iFGF23 and cFGF23 in haemodialysis patients differently according to the type of iron
used.
Methods: Prevalent, stable haemodialysis patients requiring protocol-based intravenous iron therapy were randomized
to a single 200 mg dose of either ferric carboxymaltose (FCM) or iron sucrose (IS). The primary outcome was change in
iFGF23 and cFGF23 from pre-infusion to Day 2 post-infusion. Serum hepcidin, ferritin and phosphate were also measured.
Pair-wise comparisons utilised the Wilcoxon rank sum test; linear mixed models with an interaction term for treatment
and time evaluated between-group effects.
Results: Forty-two participants completed the study. In those randomized to FCM (n = 22), median (interquartile range)
values pre-infusion and Day 2, respectively, were 843 pg/mL (313–1922) and 576 pg/mL (356–1296, p = 0.05) for
iFGF23, 704RU/mL (475–1204) and 813RU/mL (267–1156, p = 0.04) for cFGF23, and 1.53 mmol/L (1.14–1.71) and 1.
37 (1.05–1.67, p = 0.03) for phosphate. These parameters did not change following IS. Both serum ferritin (p < 0.001) and
hepcidin (p < 0.001) increased in both groups, and the increase in hepcidin was greater in the FCM group (p = 0.03 for
between-group difference).
Conclusions: Contrary to iron-deficient people with normal renal function, haemodialysis patients given protocol-
driven intravenous FCM demonstrated a fall in iFGF23 and a rise in cFGF23, changes not evident with IS. This
suggests a differential effect of intravenous iron treatment according to both formulation and renal function.
Trial registration: Australian and New Zealand Clinical Trials Register ACTRN12614000548639. Registered 22 May
2014 (retrospectively registered).
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Background
Serum concentrations of fibroblast growth factor 23
(FGF23) rise early in the course of chronic kidney disease
(CKD) [1] and are strongly correlated with adverse clinical
outcomes [2, 3]. However, whether this association is
causally related or simply reflective of concurrent
pathophysiological processes is not known, for although a
modulatory role for FGF23 in phosphate homeostasis is
well recognized, substantive control over serum levels is
also exerted through intracellular proteolysis, and other
key modulatory factors are still being elucidated [4]. Spe-
cifically, recent publications suggest a regulatory effect
between FGF23 and iron homeostasis, potentially medi-
ated via hepcidin and hypoxia inducible factor (HIF) [5, 6].
A recent series of in vivo and in vitro experiments demon-
strated that the effects of inflammation and iron deficiency
on FGF23 is mediated through HIF-1α; and induction of
* Correspondence: Lawrence.McMahon@easternhealth.org.au;
lawrence.mcmahon@monash.edu
1Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia
2Department of Renal Medicine, Eastern Health, Box Hill, VIC, Australia
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Roberts et al. BMC Nephrology  (2016) 17:177 
DOI 10.1186/s12882-016-0391-7
functional iron deficiency by administration of exogenous
hepcidin increased osseous FGF23 mRNA expression and
serum levels of inactive c-terminal FGF23 (cFGF23),
whereas concentrations of the intact molecule (iFGF23)
were unaffected [7].
Intravenous iron is widely and extensively used to man-
age iron deficiency anaemia in people without and with
CKD [8, 9], and effects on circulating FGF23 concentra-
tions have proven variable. Increased levels of iFGF23
(with post-infusion hypophosphatemia) have been demon-
strated in people without CKD in case reports [10, 11] as
well as one prospective study [12]; and a randomized con-
trolled trial of iron-deficient women showed an increase
in iFGF23 but dramatically reduced cFGF23 following
intravenous ferric carboxymaltose [13]. Administration of
intravenous iron dextran [14] or saccharated ferric oxide
[15] increased iFGF23 in separate studies of haemodialysis
(HD) patients, without cFGF23 being measured.
No randomised studies of changes in FGF23 following
intravenous iron have been conducted in HD patients.
We therefore aimed to determine whether treatment of
HD patients with two commonly used formulations at
standard doses affected iFGF23 and cFGF23 differently.
Methods
The D-IDENTIFY Study compared two formulations of
intravenous iron therapy, ferric carboxymaltose (FCM)
and iron sucrose (IS), in stable HD patients. The study
was approved by the Eastern Health Human Research
Ethics Committee (E13-1314) and study conduct ad-
hered to the Declaration of Helsinki.
Participants
Prevalent patients were recruited from HD units attached
to a single centre (Eastern Health) if they were (1) receiving
thrice-weekly HD for 3 months or more at the time of
enrolment, (2) aged 18–90 years, and (3) required intraven-
ous iron therapy based on protocol guidelines. Exclusion
criteria were (1) inability to give written informed consent,
(2) clinical evidence of active infection, (3) active malig-
nancy, (4) receipt of a blood transfusion within the preced-
ing 4 weeks, (5) severe anemia defined as hemoglobin
<85 g/L, (6) previous hypersensitivity to intravenous IS or
FCM, and (7) recent (within last 4 weeks) introduction or
change in dose of erythropoiesis stimulating agent (ESA),
phosphate binders, vitamin D analogues, or cinacalcet.
Furthermore, no participant received iron in the preceding
6 weeks before recruitment. If patients had received iron at
time of screening, they could be re-screened 6 weeks after
the last dose.
The national guidelines recommend intravenous iron
for anemic patients receiving an ESA when serum fer-
ritin is <200 μg/L or iron saturation <20%, and for those
not receiving an ESA when serum ferritin is <100 μg/L
or iron saturation <20% [16]. At our institution, iron
studies are measured every 2 months and patients
receive five weekly doses of 100 mg of iron when the
above criteria are met. Patients can receive iron if they
fall outside of the ferritin and iron saturation ranges if
the clinician feels there are other reasons why iron
might be indicated.
Procedures
After obtaining written informed consent and confirming
that participants met the criteria for intravenous iron, par-
ticipants were randomized to either intravenous FCM
(Ferinject, Vifor Pharma Australia Pty Ltd) 200 mg or IS
(Venofer, Aspen Pharmacare Australia Pty Ltd) 200 mg,
each administered as a single dose. We chose to give a
higher single dose than the usual 100 mg (weekly) dose
because participants could not receive further intravenous
iron until end of study (42 days). A dose of 500 mg or
above, as is given to people not requiring dialysis, were
considered too far from clinical practice in HD patients.
Randomization was performed using a permuted block
design with block sizes of 2, 4, 6 and 8, and allocation
was within blocks in a 1:1 ratio using the ‘random allo-
cation’ function of Stata version 11.2 (College Station,
Texas). Investigators and participants were not blinded
to treatment allocation but both were unaware of test
results during the study.
After randomization, clinical and demographic data
were collected and blood was taken on Days −14, −7, as
well as immediately pre-infusion, and Days 2, 7, 21 and
42 post-infusion. Samples were collected from the arter-
ial needle into serum and EDTA tubes before HD, left to
stand and clot (serum), centrifuged within 3 h, and then
aliquots of serum and plasma were stored at −80 °C for
subsequent analysis.
Study endpoint
The primary endpoint was the change in iFGF23 and
cFGF23 from Baseline to Day 2 after administration of
intravenous iron therapy. Secondary endpoints included
the change in serum hepcidin, ferritin and phosphate.
Sample analysis
Both iFGF23 and cFGF23 were measured in duplicate by
enzyme-linked immunosorbent assays (ELISA) with a hu-
man FGF23 immunometric assay, and reported as pg/mL
(Kainos, Shizuoka, Japan), and RU/mL (Immutopics, San
Clemente, USA), respectively. In our laboratory, the intra-
plate co-efficient of variation (CV) using duplicates from
the patient cohort was 5.8% for iFGF23 and 5.7% for
cFGF23. These two FGF23 assays do not have clinically
significant pre-analytic stability issues [17].
Serum hepcidin concentrations were measured by tan-
dem mass spectrometry using a published method [18]
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which was updated using a Waters ACQUITY Ultra-
Performance Liquid Chromatography system with a Xevo
TQ-S mass spectrometer [19] (described in detail in this
reference’s online supplement). All other laboratory ana-
lyses were performed by the clinical laboratory service
at Eastern Health, a National Association of Testing
Authorities accredited service.
Statistical analysis
From a previous randomized controlled trial [13], it was
considered a sample size of 20 participants in each group
would provide 90% power to detect a within-group and
between-group change of 0.8 times the baseline standard
deviation of FGF23 concentrations.
Measurements at Study Days −14, −7 and 0 were
used to estimate pre-infusion week-to-week variation in
iFGF23. The within-subject CV was derived from the
variance of the residuals of the multilevel mixed-effects
linear regression with random effects at the participant
level. Because of this result, we used the mean of the
three pre-infusion iFGF23 measures as the baseline
value for iFGF23. For the other variables, the single serum
sample taken immediately prior to the iron infusion was
used.
We created linear mixed models to assess the change
in measured variable from baseline to following iron
infusion. As fixed effects, we included iron formulation
(FCM versus IS) and time, and for random effects we
included a random intercept for participants. To deter-
mine whether the change in measured variable following
the iron infusion differed by iron formulation, an inter-
action term for treatment and time was introduced. As
the models included observations at each time point, the
p value for interaction for the change at Day 2 is re-
ported. Model assumptions were tested by inspection of
plots of residuals to look for deviations from normality.
For baseline comparisons, data is presented as
mean ± standard deviation or median (interquartile
range) according to the distribution of the variable
and appropriate parametric or non-parametric tests
applied. Pair-wise comparison of Day 0 and Day 2
values of measured parameters was performed using
the Wilcoxon signed-ranks tests, as variables were not
normally distributed. Comparison of measures at all
time points with baseline adjusted for multiple com-
parisons was performed using the Kruskal-Wallis test.
Analyses were performed using Stata version 11.2
(Satacorp, College Station, Texas).
Results
Of 111 patients approached for participation, 54 de-
clined to participate and 15 met exclusion criteria
(Fig. 1) leaving 42 randomized to receive FCM (FCM
Group, n = 22) or IS (IS Group, n = 20). The baseline
clinical characteristics (Table 1) in each group were
similar. Baseline laboratory values (Table 2) were
mostly similar but iFGF23 was substantially higher at
baseline in the FCM Group, although the difference
was not statistically significant. Participants were rea-
sonably iron replete according to mean ferritin and
transferrin saturation values and 14 participants had
either ferritin or iron saturation above the guideline
targets when prescribed their iron (8 in the FCM Group
and 6 in the IS Group).
Variability of iFGF23
Based on three weekly pre-infusion measures, the
within-subject CV for iFGF23 was 25%, with 96%
between-subject variability.
Change from baseline to day 2 in randomized groups
In the FCM Group, levels of iFGF23 (p = 0.046) and
phosphate (p = 0.03) were lower at Day 2 whereas levels
of cFGF23 (p = 0.036) were increased in pair-wise com-
parisons (Fig. 2, Table 3; Additional file 1: Figure S1).
There was no significant change at Day 2 in iFGF23,
cFGF23 or serum phosphate in the IS Group. Both
serum hepcidin and ferritin increased markedly in both
groups (p < 0.001, Fig. 3 and Table 3), with hepcidin
returning to baseline more quickly than ferritin in the
FCM Group (Additional file 1: Figure S2).
A linear mixed model with an interaction term for
treatment and time demonstrated that the increase in
serum hepcidin concentration from Day 0 to Day 2 was
4.2 ng/mL (95% CI: +0.4 to +8.0) greater in the FCM
Group than the IS Group (p for interaction = 0.032).
Addition of natural log-transformed CRP to this model
to adjust for inflammation did not materially alter this
finding (p for interaction 0.027). However, the changes
in log-transformed iFGF23, cFGF23, ferritin, and serum
phosphate, were not significantly different between
treatment groups.
All time points from day 0 to day 42
Considering all time points from Day 0 to Day 42 and
adjusting for multiple comparisons, median serum hepcidin
and ferritin levels differed significantly over time in both
randomized groups, whereas iFGF23, cFGF23, and serum
phosphate did not change (Additional file 2: Table S1).
Exploratory analysis by reported daily urine volume
Exploratory analysis was performed on the whole
group to determine whether self-reported daily urine
output ≥500 mL (n = 16) versus <500 mL (n = 26) in-
fluenced the levels of iFGF23 and cFGF23. A linear
mixed model adjusted for the effect of randomized
treatment that included all measures over 42 days
demonstrated that cFGF23 was 0.80 log-units lower
Roberts et al. BMC Nephrology  (2016) 17:177 Page 3 of 11
(95% CI: −1.33 to −0.26, p = 0.003) in participants who
passed ≥500 mL/day compared to those passing
<500 mL/day. Addition of an interaction term for urine
volume and time demonstrated that cFGF23 between
Day 0 and Day 2 was 0.41 log-units lower (95% CI:
−0.70 to −0.13, p for interaction = 0.004) in participants
with urine volume ≥500 mL/day compared to
<500 mL/day (Fig. 4). Separate analyses by treatment
group demonstrated a greater lowering of cFGF23 in
participants in the IS group with higher versus lower
urine output by 0.60 log-units (−1.05 to −0.14, p for
interaction = 0.01). The corresponding log unit change for
FCM for higher versus lower urine output was −0.22
(−0.56 to +0.12, p for interaction = 0.22). These differences
were not demonstrated for iFGF23, hepcidin, ferritin or
phosphate.
Discussion
In this randomized controlled trial comparing two standard
intravenous iron formulations in HD patients, both groups
received sufficient iron to stimulate an increase in both
serum hepcidin and ferritin. Notably, the changes in hepci-
din were significantly greater in the FCM Group which, un-
like the IS Group, also displayed a modest drop in iFGF23
and serum phosphate, and a rise in cFGF23. Participants
with an arbitrarily defined higher urine output (≥500 mL)
had both a lower serum baseline cFGF23 and a greater fall
after iron infusion (both FCM and IS) compared to those
with lower daily urine volumes (<500 mL).
The direction and degree of change in iFGF23 and
cFGF23 in our study differ from previous prospective
studies, which demonstrated an increase in iFGF23
following iron, and a fall in cFGF23 [13, 20] (Table 4).
Important differences between these past studies and
ours include baseline ferritin and transferrin saturation
values, the level of kidney function and the iron infusion
regimens. Iron deficiency anaemia itself is associated
with higher levels of FGF23 in laboratory [5] and clinical
studies [13], and so the degree of iron availability in par-
ticipants may influence baseline levels of FGF23. Our
participants were not iron deficient in the accepted sense
but did require intravenous iron according to a standar-
dised protocol. Furthermore, we administered a single
200 mg dose. Prior studies in HD patients administered
either a much higher dose (mean 450 ± 131 mg) [14], or
multiple smaller doses at each HD session over 3 weeks
[15]. We did not do this because we wanted to see the
effect of a single dose over time, rather than cumulative
effects of multiple doses.
Kidney dysfunction itself is known to affect the relative
levels of iFGF23 and cFGF23. In CKD, the transcription
and release of iFGF23 is thought to be partially
uncoupled, with a reduced rate of cleavage to inactive
N-terminal and C-terminal fragments [4]. C-terminal
Fig. 1 CONSORT Flow diagram of patient enrolment
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FGF23 fragments as a proportion of the total FGF23,
determined by volumetric quantitation of Western Blot
analysis at appropriate molecular weights of 14 kDa
(cFGF23) and 32 kDa (iFGF23), decline as renal function
falls: 21–56% with normal kidney function, 19% in pre-
dialysis CKD patients, and 5% in HD patients [21]. The
relatively low level of cFGF23 in HD patients, which was
not measured in the previous studies in HD patients [14,
15], may explain why we did not demonstrate a fall in
this marker, as others have in non-HD patients. Further-
more, residual kidney function in HD patients appears
to affect FGF23 regulation and its ability to stimulate
urinary phosphate excretion, possibly through an associ-
ated deficiency in Klotho. We did not assess phosphate
excretion, and so could not determine whether changes
in serum phosphate were explained by enhanced excre-
tion (via sodium-phosphate co-transporters) or mediated
by another mechanism such as intracellular uptake. It is
also unclear precisely when the changes in phosphate
occurred. However, the greater reduction in cFGF23
after iron infusion in participants with a higher urine
output, a change akin to what was seen in the non-HD
studies [13, 20], suggests that residual renal function in
HD patients may affect the response to intravenous iron
as well as modulate circulating FGF23 concentrations in-
dependent of serum phosphate. These data raise the
question whether FGF23 is able to modulate fractional
phosphate excretion in the face of reduced kidney func-
tion, and whether urine output is relevant to iron and
phosphate homeostasis even in the end-stage kidney
Table 1 Baseline characteristics of participants by treatment allocation to ferric carboxymaltose or iron sucrose
Ferric carboxymaltose (n = 22) Iron sucrose (n = 20) P
Age 70.9 (66.7–76.8) 75.1 (56.1–79.8) 0.58
Male sex 16 (73%) 14 (70%) 0.85
Diabetes 6 (27%) 9 (45%) 0.23
Cardiovascular disease 14 (64%) 15 (75%) 0.43
History of parathyroidectomy 1 (5%) 1 (5%) 0.95
Cause of ESKD 0.82
Diabetes 5 (23%) 6 (30%)
Glomerulonephritis 2 (9%) 2 (10%)
Vascular 3 (14%) 4 (20%)
Other 12 (55%) 8 (40%)
Haemodialysis (hr per week) 13.5 ± 1.5 13.2 ± 1.6 0.52
URR (%) 77.6 ± 5.8 75.3 ± 6.4 0.23
Dialysis vintage (months) 44.3 (21.7–76.6) 34.6 (18.9–64.6) 0.35
Dry weight (kg) 76.9 ± 15.8 76.8 ± 15.0 0.99
Urine volume ≥500 mL/day 7 (32%) 9 (45%) 0.38
BMI (kg/m2) 26.5 ± 4.2 27.8 ± 5.4 0.41
SBP (post-dialysis) 130.0 ± 20.0 130.8 ± 24.9 0.91
DBP (post-dialysis) 64.0 ± 14.2 59.0 ± 16.0 0.29
Medications
ESA (epoetin-β equivalent, U/week) 3800 (0–5000) 2000 (0–5800) 0.62
Receiving any ESA 16 (73%) 11 (55%) 0.23
1,25(OH2) Vit D 12 (55%) 8 (40%) 0.35
25(OH) Vit D 9 (41%) 6 (30%) 0.46
Cinacalcet 12 (55%) 7 (35%) 0.20
Calcium carbonate (500 mg/ 600 mg) 13 (59%) 9 (45%) 0.36
Lanthanum 11 (50%) 9 (45%) 0.75
Sevelamer 7 (32%) 8 (40%) 0.58
Multiple binders 10 (45%) 6 (30%) 0.30
URR urea reduction ratio, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, ESA erythropoiesis stimulating agent
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Fig. 2 Median (interquartile range) levels over the course of the study of iFGF23 (pg/mL), cFGF23 (RU/mL) and phosphate (mmol/L) in participants
treated with iron sucrose (left panels) and ferric carboxymaltose (right panels)
Table 2 Laboratory variables of participants by treatment allocation to ferric carboxymaltose or iron sucrose
Ferric carboxymaltose n = 22 Iron sucrose n = 20 P
Hemoglobin (g/L) 111 ± 9 115 ± 10 0.14
Iron (μmol/L) 14.0 (11.0–16.0) 10.5 (8.5–17.5) 0.31
Ferritin (μg/L) 211 ± 133 187 ± 130 0.55
Transferrin Saturation (%) 29 ± 9 27 ± 12 0.64
Transferrin (g/L) 2.2 ± 0.4 2.2 ± 0.5 0.65
Hepcidin (ng/mL) 7.8 (2.7–12.6) 3.4 (2.7–8.8) 0.24
iFGF23 (pg/mL) 843 (313–1922) 381 (245–1526) 0.33
cFGF23 (RU/mL) 704 (475–1204) 710 (448–1548) 0.76
PTH (pmol/L) 40.0 (20.6–68.3) 31.2 (16.6–42.2) 0.22
Ca (corrected) (mmol/L) 2.30 ± 0.17 2.31 ± 0.15 0.90
PO4 (mmol/L) 1.53 ± 0.44 1.42 ± 0.44 0.41
Albumin (g/L) 35.5 ± 2.5 34.6 ± 2.8 0.27
CRP (mg/L) 4.5 (2.0–6.0) 3.0 (2.0–5.0) 0.33
RU/mL relative units per mL, CRP C-reactive protein
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disease population. No studies have yet been performed
on dialysis patients with significant residual renal
function.
In this randomized controlled trial, we were able to
confirm that responses to different iron formulations
can vary, as demonstrated previously in iron-deficient
women [13]. In our study, serum hepcidin increased
markedly in both groups following iron infusion, but to
a greater extent in the FCM Group, despite equivalent
doses of elemental iron. Furthermore, at least at the
limited time points studied, the rise in hepcidin ap-
peared to occur before the increase in ferritin. No asso-
ciations or correlations were identified between the
hepcidin response and change in FGF23, and it is un-
clear what the different mediating effects on hepcidin
might be other than the significant differences
Fig. 3 Median (interquartile range) levels over the course of the study of serum hepcidin (ng/mL), ferritin (μg/L) and haemoglobin (g/L) in participants
treated with iron sucrose (left panels) and ferric carboxymaltose (right panels)
Table 3 Median (inter-quartile range) levels of iFGF23, cFGF23, hepcidin, ferritin and phosphate at Day 0 and Day 2, according to
randomized treatment group
Ferric carboxymaltose (n = 22) Iron sucrose (n = 20)
Day 0 Day 2 P Day 0 Day 2 P
iFGF23 (pg/mL) 843 (313–1922) 576 (356–1296) 0.046 381 (245–1526) 378 (235–1584) 0.77
cFGF23 (RU/mL) 704 (475–1204) 813 (267–1156) 0.036 710 (448–1548) 646 (307–1576) 0.23
Ferritin (μg/L) 198 (129–276) 327 (281–472) <0.001 191 (77–237) 370 (218–475) <0.001
Hepcidin (ng/mL) 7.8 (2.7–12.6) 21.4 (13.9–26.2) <0.001 3.4 (2.7–8.8) 12.2 (7.3–19.2) <0.001
Phosphate (mmol/L) 1.53 (1.14–1.71) 1.37 (1.05–1.67) 0.030 1.29 (1.11–1.65) 1.34 (1.08–1.54) 0.089
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associated with respective formulations. Inherent struc-
tural differences in the carbohydrate shell of the re-
spective iron formulations, resulting in different rates
of release of labile iron into the serum [22] may at least
be a partial explanation.
The clinical importance of differences in FGF23 stimu-
lation between iron formulations can be considered im-
mediate or long term. The immediate effect of FGF23 is
lowering of serum phosphate which in our study was
only modest, but has been demonstrated in other studies
(Table 4). A potential longer term effect of concern is
that higher levels of FGF23 are associated with both car-
diovascular events and death in advanced CKD [23] and
that FGF23 is associated with left ventricular hyper-
trophy (LVH) in human studies [24]. Experimental stud-
ies have identified that the LVH associated with elevated
FGF23 serum levels and mediated by its specific cardiac
receptor (Type 4) can be mitigated by blocking the re-
ceptor [25]. If an iron formulation has less effect on
FGF23 production, it may potentially have fewer adverse
cardiac effects.
Strengths of this study are that we compared iron for-
mulations in a randomized controlled trial, that we
assessed the inherent variability in iFGF23 before infu-
sion, measured both iFGF23 and cFGF23, and examined
them at an earlier time point (Day 2) than previously
studied in HD patients. Although we collected samples
at an earlier time point to measure FGF23 than previous
studies in HD patients, more frequent collection either
side of day 2 may better characterise the trajectory of
change in FGF23. The within-subject variability in
iFGF23 was a significant limitation as it reduced our
ability to detect a change in iFGF23 with time and some
reduction may have just been regression to the mean.
This high within-subject variability has also been dem-
onstrated in healthy volunteers although at a much
lower level [21], and suggests that some of the changes
demonstrated could be due to biological fluctuation. We
tried to address inherent variability by taking the mean
of 3 pre-infusion measurements, although results were
not different when the analyses were repeated using a
single baseline iFGF23 sample. To minimise between-
subject variability, the baseline sample was collected be-
fore the second (“middle”) dialysis day of the week in all
participants. In view of the variability in FGF23, the
sample size was small and increasing the sample size
may have helped to overcome this limitation. Another
way to address this would have been to include a control
group who received no iron but have FGF23 measured
at the same time points. When we commenced the
study, we were concerned about not giving iron to
patients who met the criteria for receiving intravenous
iron (based on international guidelines). However, given
the demonstrated variability of FGF23 in this group of
Fig. 4 Median levels of cFGF23 over time in participants with low (<500 mL) daily urine output (left panel) and higher (≥500 mL) daily urine output
(right panel)
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Table 4 Summary of findings compared to other prospective studies that administered intravenous iron and measured FGF23.
Study: Current study Hryszko, 2012 [14] Takeda, 2011 [15] Prats, 2013 [20] Wolf, 2013 [13] Schouten, 2009 [12]




20 22 12 27 47 25 30 8
Baseline ferritin
(μg/L)
187 ± 130 211 ± 133 64.4 ± 32.7 31 ± 23 67.8 ± 61.7 4.4 ± 0.6 6.9 ± 1.7
Iron formulation IS FCM Iron dextran Saccharated ferric
oxide








mean = 450 mg
9 doses of 40 mg after
dialysis (total = 360 mg)
1 dose (15 mg/kg to
a maximum of 1000 mg,
mean = 972 mg)
1 dose (15 mg/kg to a maximum
of 1000 mg, mean = 918 mg)
1 dose (15 mg/kg to
a maximum1,000 mg,
mean = 911 mg)








Weeks 1 & 3 Weeks 1, 3 & 5 Week 3 & 12 Days 1, 7, 14, 28 & 35 Days 1, 7, 14, 28 & 35 Weekly for up to
7 weeks
iFGF23 − ↓ ↑ ↑ ↑a − ↑↑
cFGF23 − ↑ ↓ ↓↓ ↓↓
Ferritin ↑↑ ↑↑ ↑ ↑ ↑ ↑↑a ↑
Hepcidin ↑ ↑↑a ↑ ↑↑a
Phosphate − ↓ − − ↓ ↓ − ↓
CKD chronic kidney disease, iFGF23 intact fibroblast growth factor 23, cFGF23 c-terminal fibroblast growth factor 23, HD haemodialysis patients, FCM ferric carboxymaltose, IS iron sucrose
Blank cells indicate that the analyte was not measured, ‘-’ indicates no change












patients, this will be an important consideration for
future studies.
Conclusion
Infusion of 200 mg of intravenous FCM to non-iron-
deficient, stable HD patients resulted in a significant
reduction in iFGF23 and phosphate, and a rise in
cFGF23. Little if any change was seen in the IS Group
and no between-group changes were identified for these
variables. Evidence of altered iron handling was estab-
lished with marked increases in hepcidin and ferritin,
with a significant between-group difference in hepcidin
(and greater rise in the FCM Group). Residual urine out-
put might also have had an effect on FGF23 concentra-
tions in this end-stage kidney disease population. Future
studies examining the effect of iron on the regulation of
FGF23 transcription and proteolysis should take into
account the greatly augmented serum concentrations
and substantial variability of FGF23 in this population,
and the different iron handling responses to different
formulations.
Additional files
Additional file 1: Figures S1 and S2. Figure S1. The individual
participant levels of iFGF23 (pg/mL), cFGF23 (RU/mL) and phosphate
(mmol/L) over the course of the study for participants randomized to
iron sucrose (left panels) and ferric carboxymaltose (right panels). Figure
S2. The individual participant levels of serum hepcidin (ng/mL) ferritin
(μg/L), and haemoglobin (g/L) over the course of the study for
participants randomized to iron sucrose (left panels) or ferric
carboxymaltose (right panels). (PDF 670 kb)
Additional file 2: Table S1. Median (IQR) levels of iFGF23, cFGF23,
ferritin, hepcidin and phosphate at Day 0, 2, 7, 21 and Day 42, by
randomized treatment group. (PDF 93 kb)
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